                         SEQUENCE LISTING

<110>  Biokine Therapeutics Ltd.
       PELED, Amnon
 
<120>  COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES

<130>  64779

<150>  US 62/089,411
<151>  2014-12-09

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide
<400>  12

Ser Ile Pro Ser His Ser Ile His Ser Ala Lys Ala 
                                                        12


<210>  2
<211>  283
<212>  PRT
<213>  Artificial sequence

<220>
<223>  BKT-P2-FC polypeptide
<400>  283

Met Asn Ser Phe Ser Thr Ser Ala Phe Gly Pro Val Ala Phe Ser Leu 
1               5                   10                  15      


Gly Leu Leu Leu Val Leu Pro Ala Ala Phe Pro Ala Pro Val Pro Pro 
            20                  25                  30          


Ser Ile Pro Ser His Ser Ile His Ser Ala Lys Ala Gly Gly Gly Ser 
        35                  40                  45              


Lys Gly Phe Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 
    50                  55                  60                  


Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 
65                  70                  75                  80  


Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 
                85                  90                  95      


Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 
            100                 105                 110         


Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 
        115                 120                 125             


Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 
    130                 135                 140                 


Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 
145                 150                 155                 160 


Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 
                165                 170                 175     


Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 
            180                 185                 190         


Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 
        195                 200                 205             


Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 
    210                 215                 220                 


Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 
225                 230                 235                 240 


Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 
                245                 250                 255     


Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 
            260                 265                 270         


Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
        275                 280            


<210>  3

<211>  233
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Human IgG1 Fc (Fc N297A)
<400>  233

Phe Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 
1               5                   10                  15      


Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 
            20                  25                  30          


Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 
        35                  40                  45              


Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 
    50                  55                  60                  


Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 
65                  70                  75                  80  


Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 
                85                  90                  95      


Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 
            100                 105                 110         


Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 
        115                 120                 125             


Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 
    130                 135                 140                 


Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 
145                 150                 155                 160 


Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 
                165                 170                 175     


Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 
            180                 185                 190         


Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 
        195                 200                 205             


Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 
    210                 215                 220                 


Lys Ser Leu Ser Leu Ser Pro Gly Lys 
225                 230             


<210>  4

<211>  32
<212>  PRT
<213>  Artificial sequence

<220>
<223>  IL6 signal peptide
<400>  32

Met Asn Ser Phe Ser Thr Ser Ala Phe Gly Pro Val Ala Phe Ser Leu 
1               5                   10                  15      


Gly Leu Leu Leu Val Leu Pro Ala Ala Phe Pro Ala Pro Val Pro Pro 
            20                  25                  30          


<210>  5

<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Hexapeptide spacer sequence

<400>  6

Gly Gly Gly Ser Lys Gly 
1               5       


<210>  6

<211>  852
<212>  DNA
<213>  Artificial sequence

<220>
<223>  IL6-P2-Fc N297A DNA coding sequence
<400>  852
atgaacagct tcagcaccag cgccttcggc cccgtggcct tcagcctggg cctgctgctg       60

gtgctgcctg ccgccttccc tgcccccgtg ccccccagca tccccagcca cagcatccac      120

agcgccaagg ccggcggcgg cagcaagggc ttcgaaccca agagctgtga caagacccac      180

acctgccccc cttgccctgc ccctgagctg ctgggcggac ccagcgtgtt cctgttccct      240

cccaagccta aggacaccct gatgatcagc agaacccccg aggtgacctg tgtggtggtg      300

gatgtgagcc acgaggaccc tgaggtgaag ttcaactggt acgtggacgg cgtggaggtg      360

cacaatgcca agaccaagcc cagggaggag cagtacgcca gcacctaccg ggtggtgtcc      420

gtgctgaccg tgctgcacca ggattggctg aacggcaagg aatacaagtg taaggtgtcc      480

aacaaggccc tgcctgcccc tatcgagaaa accatcagca aggccaaggg ccagcctagg      540

gagccccagg tgtacaccct gccccctagc agagatgagc tgaccaagaa tcaggtgtcc      600

ctgacctgcc tggtgaaggg cttctacccc agcgacatcg ccgtggagtg ggagagcaac      660

ggccagcccg agaacaacta caagaccacc ccccctgtgc tggacagcga tggcagcttc      720

ttcctgtaca gcaagctgac cgtggataag agcagatggc agcagggcaa cgtgttcagc      780

tgctccgtga tgcacgaggc cctgcacaat cactacaccc agaagagcct gagcctgtcc      840

cctggcaagt ga                                                          852

